| Literature DB >> 30215631 |
So Yeon Paek1,2, Jillian Frieder3, Dario Kivelevitch3, M Alan Menter3,2.
Abstract
The role of the Th17/interleukin (IL)-23 pathway has been well elucidated in psoriasis. The IL-17 family includes 6 cytokines: IL-17A, IL-17B, IL-17C, IL-17D, IL-17E, and IL-17F. Two monoclonal antibodies targeting IL-17A (secukinumab, ixekizumab) and one antibody against the IL-17 receptor (brodalumab) have been approved for the treatment of moderate-to-severe plaque psoriasis. Clinical efficacy, safety, and tolerability of each agent is reviewed. ©2018 Frontline Medical Communications.Entities:
Mesh：
Substances：
Year: 2018 PMID： 30215631 DOI： 10.12788/j.sder.2018.051
Source DB: PubMed Journal: Semin Cutan Med Surg ISSN： 1085-5629